Nom du produit:4-bromo-2,6-difluorobenzaldehyde
IUPAC Name:4-bromo-2,6-difluorobenzaldehyde
- CAS：537013-51-7
- Formule moléculaire：C7H3BrF2O
- Pureté：98%
- Numéro de catalogue：CM100417
- Poids moléculaire：221
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:537013-51-7
- Formule moléculaire:C7H3BrF2O
- Point de fusion:-
- Code SMILES:O=CC1=C(F)C=C(Br)C=C1F
- Densité:1.758 g/cm3
- Numéro de catalogue:CM100417
- Poids moléculaire:221
- Point d'ébullition:
- N° Mdl:MFCD03094459
- Stockage:Keep in Inert atmosphere, store at 2-8°C.
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Carbonyl Compounds
- In organic chemistry, a carbonyl group is a functional group with the formula C=O, composed of a carbon atom double-bonded to an oxygen atom, and it is divalent at the C atom. It is common to several classes of organic compounds (such as aldehydes, ketones and carboxylic acids), as part of many larger functional groups. A compound containing a carbonyl group is often referred to as a carbonyl compound.
- Giredestrant
- Giredestrant (GDC-9545) is under development by Roche/Genentech. Giredestrant is a potent, next generation investigational selective oestrogen receptor (SERD) with best-in-class potential. In the phase 2 coopERA trial, postmenopausal patients with untreated ER+/HER2- early breast cancer were randomly assigned to receive neoadjuvant combination therapy with palbociclib and giredestrant or anastrozole, followed by surgical intervention within 14 days. The tumor biomarker Ki67 of the patients was ≥ 5% when they were enrolled in the group. The analysis showed that patients receiving giredestrant combination therapy (mean Ki67 reduction of 80%) had a greater mean reduction in Ki67 levels from baseline at week 2 compared with anastrozole combination therapy (mean Ki67 reduction of 67%). The pivotal phase 3 trial of giredestrant is recruiting patients and preliminary data is expected in 2025.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
